[go: up one dir, main page]

EP3938365A4 - Compositions et procédés pour traiter des formes positives de récepteurs des androgènes du cancer - Google Patents

Compositions et procédés pour traiter des formes positives de récepteurs des androgènes du cancer Download PDF

Info

Publication number
EP3938365A4
EP3938365A4 EP20774663.7A EP20774663A EP3938365A4 EP 3938365 A4 EP3938365 A4 EP 3938365A4 EP 20774663 A EP20774663 A EP 20774663A EP 3938365 A4 EP3938365 A4 EP 3938365A4
Authority
EP
European Patent Office
Prior art keywords
cancer
compositions
methods
androgen receptor
receptor positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20774663.7A
Other languages
German (de)
English (en)
Other versions
EP3938365A1 (fr
Inventor
Maureen Caligiuri
Anna Ericsson
Sylvie GUICHARD
Qunli Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/039936 external-priority patent/WO2020006483A1/fr
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of EP3938365A1 publication Critical patent/EP3938365A1/fr
Publication of EP3938365A4 publication Critical patent/EP3938365A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20774663.7A 2019-03-15 2020-03-13 Compositions et procédés pour traiter des formes positives de récepteurs des androgènes du cancer Pending EP3938365A4 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962819482P 2019-03-15 2019-03-15
US201962819472P 2019-03-15 2019-03-15
US201962819476P 2019-03-15 2019-03-15
US201962819490P 2019-03-15 2019-03-15
US201962819487P 2019-03-15 2019-03-15
US201962821660P 2019-03-21 2019-03-21
PCT/US2019/039936 WO2020006483A1 (fr) 2018-06-29 2019-06-28 Inhibition de la protéine de liaison à creb (cbp)
PCT/US2020/022823 WO2020190792A1 (fr) 2019-03-15 2020-03-13 Compositions et procédés pour traiter des formes positives de récepteurs des androgènes du cancer

Publications (2)

Publication Number Publication Date
EP3938365A1 EP3938365A1 (fr) 2022-01-19
EP3938365A4 true EP3938365A4 (fr) 2023-01-25

Family

ID=72521203

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20774663.7A Pending EP3938365A4 (fr) 2019-03-15 2020-03-13 Compositions et procédés pour traiter des formes positives de récepteurs des androgènes du cancer

Country Status (7)

Country Link
EP (1) EP3938365A4 (fr)
CN (1) CN113784967B (fr)
AU (1) AU2020241709B2 (fr)
BR (1) BR112021018266A2 (fr)
CA (1) CA3132995A1 (fr)
MX (1) MX2021011154A (fr)
WO (1) WO2020190792A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150156A2 (fr) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Composés hétéroarylés et leurs procédés d'utilisation
EP2412710A1 (fr) * 2009-03-27 2012-02-01 Kowa Company, Ltd. Composé de pipéridine condensé et agent pharmaceutique le contenant
WO2016086200A1 (fr) * 2014-11-27 2016-06-02 Genentech, Inc. Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300
WO2019055877A1 (fr) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
WO2020006483A1 (fr) * 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibition de la protéine de liaison à creb (cbp)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3071203T3 (da) * 2013-11-18 2021-03-15 Forma Therapeutics Inc Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer
WO2017197056A1 (fr) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412710A1 (fr) * 2009-03-27 2012-02-01 Kowa Company, Ltd. Composé de pipéridine condensé et agent pharmaceutique le contenant
WO2011150156A2 (fr) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Composés hétéroarylés et leurs procédés d'utilisation
WO2016086200A1 (fr) * 2014-11-27 2016-06-02 Genentech, Inc. Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300
WO2019055877A1 (fr) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
WO2020006483A1 (fr) * 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibition de la protéine de liaison à creb (cbp)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020190792A1 *

Also Published As

Publication number Publication date
MX2021011154A (es) 2021-10-22
BR112021018266A2 (pt) 2022-02-01
AU2020241709A1 (en) 2021-09-23
AU2020241709B2 (en) 2025-12-04
EP3938365A1 (fr) 2022-01-19
CN113784967A (zh) 2021-12-10
CN113784967B (zh) 2024-07-26
WO2020190792A1 (fr) 2020-09-24
CA3132995A1 (fr) 2020-09-24

Similar Documents

Publication Publication Date Title
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
EP3526202A4 (fr) Composés et procédés pour la dégradation ciblée du récepteur des androgènes
EP3634424A4 (fr) Compositions et procédés pour prévenir ou traiter des affections musculaires
MA56050A (fr) Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
EP3864152A4 (fr) Procédés et compositions pour éditer des arn
AU2018288555A1 (en) Methods and compositions for treatment of concrete wash water
EP4081518A4 (fr) Associations d'agents de dégradation du récepteur d'?strogènes et d'inhibiteurs de kinase dépendante de cyclines pour le traitement du cancer
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3990920A4 (fr) Procédés et compositions pour ligature de proximité
EP3793562A4 (fr) Procédés et compositions pour inhiber la dihydroorotate déshydrogénase
MA55087A (fr) Compositions et procédés de traitement de laminopathies
PT3807316T (pt) Composições e métodos para tratamento de cancro
EP4041511A4 (fr) Procédés et compositions pour le traitement d'eau recyclée issue de la production du béton
EP3924478A4 (fr) Compositions et procédés pour traiter la glycogénose de type 1a
EP3775171A4 (fr) Procédés de traitement d'un cancer résiduel minimal
EP3403099A4 (fr) Procédés et compositions pour le traitement du cancer
EP3478284A4 (fr) Composés et compositions pour le traitement du cancer
EP3801590A4 (fr) Compositions et procédés de traitement du psoriasis
EP3531966A4 (fr) Dispositifs et procédés pour l'atténuation de l'incontinence fécale
EP3873540A4 (fr) Procédés et matériaux pour le traitement du cancer
MA55531A (fr) Procédés pour le traitement de béta-thalassémie
EP2558112A4 (fr) Compositions et procédés pour traiter une exacerbation de bpco

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211015

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40067268

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20221223

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20221219BHEP

Ipc: A61K 31/437 20060101ALI20221219BHEP

Ipc: C07D 471/04 20060101AFI20221219BHEP